# Exosome injections

Source: https://onco.cc/technologies/rejuv-frontier-exosome-injections/  
OnCo record `rejuv-frontier-exosome-injections` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exosomes are real biology and a serious research field. Exosome injections sold in clinics are neither. There are no approved exosome products anywhere, and the FDA issued a public safety notification after patients in Nebraska were seriously harmed by them.

## Summary

Exosomes are small membrane vesicles that cells release and that carry proteins and RNA between cells. As a research field they are legitimate: The engineered-delivery work has its own record on OnCo, linked below. What is sold in clinics, usually as an intravenous infusion or an injection into skin or scalp and often alongside stem cell or peptide products, is a different matter.

On 6 December 2019 the FDA issued a public safety notification on exosome products after serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes. The notification states that there are no FDA-approved exosome products, that exosomes used therapeutically are regulated as drugs and biological products subject to premarket review and approval, and that clinics offering them outside that process are operating unlawfully and making unsubstantiated claims. The FDA's regenerative medicine consumer page lists exosomes among the unapproved products from which it has received reports of blindness, tumour formation and infections.

There is no published randomised trial of an exosome preparation for recovery, hair, skin, fatigue or biological age in cancer survivors, and no characterisation standard that would let one clinic's preparation be compared with another's.

## Fields

- Kind: Technology
- Status: preclinical
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:harm; unproven; regulator-warning
- Principle: No mechanism can be stated for the marketed products, because what is in the vial is not disclosed or standardised: source cell line, isolation method, particle count, cargo and sterility all differ and are generally not reported.
- Strengths: The underlying biology is a legitimate research field with engineered-delivery applications
- Limitations: No approved exosome product exists anywhere; FDA public safety notification issued after serious adverse events in patients in Nebraska; No randomised trial in cancer survivors for any claimed use; No standardisation, so no dose, potency or sterility assurance; Sold privately at a price, often bundled with stem cell or peptide products

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Exosome
- FDA: Public safety notification on exosome products (6 December 2019): https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
- FDA: Important patient and consumer information about regenerative medicine therapies (3 June 2021): https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

## Connected records

- technologies: [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [Engineered exosomes as drug carriers](https://onco.cc/technologies/exosome-therapeutics/), [Stem cell clinics and stem cell tourism](https://onco.cc/technologies/rejuv-frontier-stem-cell-tourism/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-frontier-exosome-injections.json